Cohance Lifesciences Ltd
COHANCE
Company Profile
Business description
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
Contact
Hitech City Road, Panmaktha Plot, 1
202, 2nd Floor, B-Wing, Galaxy by Aurobindo Realty, Sy No 83/1
Hyderabad Knowledge City TSIIC Raidurg
Opposite IKEA
HyderabadTG500081
INDT: +91 4044758595
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
1,052
Stocks News & Analysis
stocks
Distribution growth for ASX income play
Cost containment and growing revenue bode well for profit margins.
stocks
We take a different view to market on ASX bloodbath
Sales growth at CSL was lower than expected but streamlining the business has its perks.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,284.20 | 51.60 | 0.56% |
| CAC 40 | 7,956.00 | 17.03 | -0.21% |
| DAX 40 | 24,264.41 | 12.56 | -0.05% |
| Dow JONES (US) | 44,938.31 | 16.04 | 0.04% |
| FTSE 100 | 9,297.23 | 9.09 | 0.10% |
| HKSE | 25,067.22 | 98.72 | -0.39% |
| NASDAQ | 21,172.86 | 142.09 | -0.67% |
| Nikkei 225 | 42,610.17 | 278.38 | -0.65% |
| NZX 50 Index | 13,194.07 | 122.77 | 0.94% |
| S&P 500 | 6,395.78 | 15.59 | -0.24% |
| S&P/ASX 200 | 9,019.10 | 45.40 | 0.51% |
| SSE Composite Index | 3,771.10 | 4.89 | 0.13% |